Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice

Elisabeth Schorb(University Medical Center Freiburg), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Kim Linton(The Christie NHS Foundation Trust), Benjamin Kasenda(University Hospital of Basel), Slavisa Ninkovic(University College Hospital), Kate Cwynarski(University of Leeds), Mauro Krampera(University of Verona), Stefan Trefz(Klinikum Stuttgart), Nicolás Martínez‐Calle(Nottingham University Hospitals NHS Trust), Alberto Fabbri(Azienda Ospedaliera Universitaria Senese), Jeffery Smith(University of Liverpool), Toby A. Eyre(Churchill Hospital), Deborah Yallop(King's College Hospital NHS Foundation Trust), Lorella Orsucci(Azienda Ospedaliero Universitaria San Giovanni Battista), Beatrice De Marco(University of Verona), Christopher P. Fox(Nottingham University Hospitals NHS Trust), Teresa Calimeri(Vita-Salute San Raffaele University), Tom Cummin(Cancer Research UK), Gerald Illerhaus(Klinikum Stuttgart)
British Journal of Haematology
January 29, 2020
10.1111/bjh.16451
Cited by 69

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523